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Background: Reversible histone acetylation affects chro-
matin structural organization, thus regulating gene expres-
sion and other nuclear events. Levels of histone acetyla-
tion are tightly modulated in normal cells, and alterations
of their regulating mechanisms have been shown to be
involved in tumorigenesis.
Methods: We developed a new ﬂow cytometric techni-
que for detection of histone acetylation, based on a speci-
ﬁc monoclonal antibody that recognizes acetylated his-
tone tails. Bivariate analysis for histone acetylation levels
and DNA were performed to study modulation of chroma-
tin organization during the cell cycle and after induction
of histone hyperacetylation by the histone deacetylase
(HDAC) inhibitor trichostatin A (TSA). Histone acetylation
and transcription levels were monitored during differen-
tiation induced by retinoic acid alone or in combination
with TSA. Blood samples from patients were analyzed
with the described protocol to monitor the effects of
HDAC inhibitors in vivo and validate the developed proto-
col for clinical usage.
Results: Flow cytometric detection of acetylation status
can successfully detect modiﬁcations induced by HDAC
inhibitor treatment in vivo as demonstrated by analysis
of various blood samples from patients treated with val-
proic acid. Changes in acetylation levels during the cell
cycle demonstrated a reproducible increase in histone
acetylation during the replication phase that was subse-
quently decreased at the G2M entrance, thus paralleling
the behavior of DNA replication and transcriptional
activity.
Conclusions: Multiparameter analysis of histone acetyla-
tion and expression of molecular markers, DNA ploidy,
and/or cell cycle kinetics can provide a quick and statisti-
cally reliable tool for the diagnosis and evaluation of
treatment efﬁcacy in clinical trials using HDAC inhibitors.
q 2005 Wiley-Liss, Inc.
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In the eukaryotic cell nucleus DNA is wrapped around
histones to constitute nucleosomes, the fundamental orga-
nizational element of chromatin. Modiﬁcations of chroma-
tin structure by histone tail acetylation, phosphorylation,
and methylation are involved in all processes regarding
DNA such as gene expression, replication, and mitotic
chromosome condensation (1). The pattern of histone
posttranslational modiﬁcations is the result of an epige-
netic code regulating gene transcription and silencing (2).
In particular, histone acetylation can affect gene expres-
sion as evidenced by the observed positive correlation
between histone 3 and 4 lysine acetylation and gene acti-
vation, while whereas hypo-acetylation is a mark of non-
transcribed DNA regions (3).
The number of acetyl groups present on histones is
regulated by the competing activities of different classes
of enzymes. Histone acetyl transferases are part of coacti-
vator complexes involved in chromatin remodeling to
initiate transcription. Histone deacetylases (HDACs) regu-
late gene silencing by removing acetyl groups from his-
tones and favoring chromatin condensation (4). Breakage
of the equilibrium between the two activities can lead to
dramatic effects on the regulation of transcriptional path-
ways, establishing the conditions for the development of
cancer.
Recent discoveries have identiﬁed key molecular events
in the pathogenesis of acute promyelocytic leukemia,
caused by chromosomal rearrangements leading to the
fusion of the retinoic acid receptor-a (RAR) gene with
other cellular genes (5–7). The resulting protein chimera
impairs retinoic acid (RA) response due to aberrant
recruitment on RA-responsive promoters of transcrip-
tional coregulators (such as SMRT/NCOR) in a HDAC asso-
ciated complex (8). Maintenance of transcriptionally
repressed chromatin state in the presence of physiologic
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concentration of RA can be therefore proposed as a neces-
sary event in the PML-RAR–mediated leukemogenesis (9).
Further studies on other leukemogenic fusion proteins
have shown that association and recruitment of HDAC
complexes and consequent aberrant gene silencing can
be a common theme in acute myelocytic leukemias
(9,10). On the basis of the above-mentioned studies in the
pathogenesis of leukemia, HDAC inhibitors (HDACi) have
been used in combination with differentiation-inducing
agents to relieve the block in hematopoietic differentia-
tion. RA and HDACi combined treatment induced a clini-
cal response in a patients with RA-resistant acute promye-
locytic leukemia (11).
HDACi have also been shown to induce differentiation,
growth arrest, and/or apoptosis in solid tumors, leading to
their consideration as multipurpose antitumoral drugs. In
fact, clinical trials have started to evaluate the efﬁcacy of
HDACi in nonleukemic patients (12).
Detection of histone acetylation levels in the cell
nucleus can therefore provide an important tool in moni-
toring the cellular response to speciﬁc anticancer treat-
ments and the production of monoclonal antibodies
recognizing hyper-acetylated histones is consequently
gaining enormous potential for research and diagnostic
applications (13). In the present study, we developed a
ﬂow cytometric protocol for detection of hyper-acetylated
histones and simultaneous cell cycle analysis based on a
speciﬁc monoclonal antibody recognizing acetylated his-
tone tails. After detection of their modulation in the cell
cycle progression, histone acetylation and transcriptional
levels were monitored during in vitro differentiation of
leukemic cells induced by RA treatment alone or in combi-
nation with trichostatin A (TSA), showing that no global
differences in transcriptional levels were caused by the
presence of the HDACi.
To evaluate the effect for clinical investigations, the pro-
tocol was ﬁrst tested on preclinical models of acute mye-
loid leukemia and then employed to analyze peripheral
blood samples from patients who were affected by differ-
ent types of cancer and enrolled in protocols making use
of HDACi (valproic acid, VPA). We demonstrated that with
the developed protocol histone hyper-acetylation can be
successfully detected in patients, thus providing a poten-




Human U-937 and NB4 leukemic cell lines were grown
in RPMI-1640 medium supplemented with 10% fetal bo-
vine serum.
Exponentially growing U-937 cells were treated for 4 h
with 50 ng/ml of TSA (Sigma, St. Louis, MO, USA). Cells
were then washed with cold phosphate buffer saline
(PBS), counted, and ﬁxed in 1% formaldehyde in PBS for
15 min. Fixed cells were then washed, resuspended in
PBS, and stocked at 4C.
Exponentially growing NB4 cells were treated for 2, 4,
24, and 48 h with 50 ng/ml of TSA and/or 1 mM RA to
induce cell differentiation. To evaluate transcriptional
activity, 5-bromouridine (BrU; Sigma) was added to cell
culture medium to a ﬁnal concentration of 4 mM during
the last 30 min of treatment. Cells were subsequently col-
lected and analyzed by ﬂow cytometry.
Blood Sample Preparation
Human peripheral blood (5 ml) was collected and
spinned down at 1,500 rpm for 5 min. Cells were incu-
bated in 3 ml of 0.1% NaCl on ice for 40 min. After addi-
tion of 3 ml of 1.6% NaCl and 10 ml of PBS, cells were
spinned down at 13,000 rpm for 10 min.
Cells were ﬁxed in 1% formaldehyde in PBS for 15 min.
Fixed cells were then washed and resuspended in PBS and
stocked at 4C to be processed for the histone acetylation
levels detection according to the protocol below.
Differentiation Analysis of Surface Markers
NB-4 cells, 5 3 105 per sample, were collected after 48 h
of RA treatment (or left untreated as control), washed
with PBS plus 1% bovine serum albumin (BSA), and incu-
bated with the monoclonal mouse anti-human CD11c anti-
body (DakoCytomation, Glostrup, Denmark; 30 mg/ml)
for 1 h at room temperature. Samples were washed and
incubated with a ﬂuorescein isothiocyanate (FITC)–conju-
gated afﬁnity pure F(ab0)2 fragment of goat anti-mouse
immunoglobulin (IgG; Sigma) for 1 h at room temperature
in the dark. Cells were then resuspended in PBS for acqui-
sition.
Analysis of Histone Acetylation/DNA Content
Cells were ﬁxed for 15 min in 1% formaldehyde in PBS
on ice and subsequently reﬁxed in 70% EtOH. Due to the
large amount of HDAC proteins present in the cells, de-
acetylation activity is very high. Consequently, the preﬁxa-
tion steps became very important for maintaining histones
in a hyper-acetylated state and avoiding artifacts. All wash-
ings were performed in a refrigerated centrifuge using
cold PBS, and cells were ﬁnally ﬁxed on ice. Removal of
cell culture medium containing TSA and substitution with
PBS can cause complete loss of the enhanced acetylation
signal, even during the few minutes needed for the pre-
ﬁxation washings (data not shown). Ethanol ﬁxation is not
compatible with acetylated histone detection; conse-
quently, a ﬁrst incubation with 1% formaldehyde was
needed before alcoholic treatment for optimal staining
with propidium iodide (PI). Cells, 1 3 106 per sample,
were washed with PBS 1 1% BSA and permeabilized with
200 ml of 0.1% Triton X-100 in PBS for 10 min at room
temperature. After washing with PBS 1 1% BSA, the sam-
ples were incubated with 500 ml of 10% normal goat
serum in PBS for 20 min. Histone acetylation levels were
detected by incubation with the T52 mouse monoclonal
antibody (5 mg/ml in PBS 1 1% BSA), T25 (1 mg/ml), and
anti-tetra-acetylated histone H4 (1:50 dilution; Upstate,
Charlottesville, VA, USA). T52 and T25 were produced by
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mouse immunization with a peptide derived from the tetra-
acetylated histone H4 tail (Fig. 1). Detection was performed
by incubation with a FITC-conjugated, afﬁnity puriﬁed
F(ab0)2 fragment of goat anti-mouse IgG (Sigma) for 1 h at
room temperature in the dark. Cells were resuspended in 1
ml of PI solution containing 2.5 mg/ml of PI in PBS and 25 ml
of RNAse (1 mg/ml in water) and stained overnight at 4C.
Analysis of Transcription/DNA Staining
For detection of transcription, cells were ﬁrst ﬁxed in
1% formaldehyde and subsequently in 70% EtOH. Cells,
1 3 106 per sample, were washed, permeabilized, and
subsequently incubated with a solution of 5 mg/ml of
mouse monoclonal anti-bromodeoxyuridine (anti-BrdUrd)
antibody (Becton Dickinson Co., Franklin Lakes, NJ, USA)
in PBS 1 1% BSA for 1 h at room temperature in the dark.
The anti-BrdUrd antibody recognizes 50-BrU and 50-BrdUrd.
After subsequent incubation with FITC-conjugated afﬁnity
pure F(ab0)2 fragment of goat anti-mouse IgG, cells were
ﬁnally resuspended in 1 ml of PI solution containing 2.5
mg/ml of PI in PBS and 25 ml of RNAase, 1 mg/ml in water,
and stained overnight at 4C in the dark.
Flow Cytometric Analysis
Flow cytometric analysis was performed by a FACScan
ﬂow cytometer (Becton Dickinson), acquiring at least
15,000 events/sample. The instrument was equipped with
a bandpass 530/30-nm optical ﬁlter for FITC ﬂuorescence
detection (FL1 channel) and a 650-nm longpass optical ﬁl-
ter in front of the PI (FL3) channel detector. Cells doublets
were discriminated by pulsed processor analysis, accord-
ing to the comparison of peak and area electronic signals
from the FL3. Cell cycle distribution analysis was per-
formed with ModFit software (Verity Software House, Top-
sham, ME, USA).
To evaluate correlation between DNA content and tran-
scription and histone acetylation levels, cell distribution
was subdivided into different classes on the base of the
FIG. 1. A:. Evaluation of the acetylation levels of histones in U937 cells after 4 h of treatment with 1 mM VPA, 50 ng/ml TSA, and 4 mM SAHA by western
blot analysis using T52 antibody against acetyl-lysine (right panel). Equal loading was veriﬁed by Ponceau staining of the membrane (left panel). B: Evalua-
tion of the of histone H4 acetylation in U937 cells after 24 h of treatment with 1 mM VPA, 50 ng/ml TSA, and 4 mM SuberoylAnilide Hydroxamic Acid
(SAHA) by western blot analysis using T25 antibody against acetyl-H4 (upper panel). Equal loading was veriﬁed using an antibody against histone H4
(Upstate; lower panel). C: Speciﬁcity of T52 clone for acetyl-lysine. Differentially acetylated H4/non H4 derived peptides, 18-aa long, were used in enzyme-
linked immunosorbent assay to determine the speciﬁcity of the T52 antibody.
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mean ﬂuorescence of PI. G1 and G2M compartments
were selected according to the peak positions and instru-
ment linearity in the FL3 channel. Intermediate DNA con-
tent was further partitioned into 12 different areas span-
ning S phase. FL1 (transcription or acetylation) mean
ﬂuorescence was then calculated and plotted for each sub-
class. To better evaluate TSA effects, the ratio between
acetylation-related mean ﬂuorescence in treated and expo-
nentially growing cells (fold increase) was calculated per
DNA compartment to unmask dependence on cell cycle
distribution.
Western Blot Analysis of Histone Acetylation
U937 cells (5 3 106) were lysed in 80 ml of lysis buffer
(50 mM Tris-HCl, pH 6.8, 10% glycerol, 4% b-mercap-
toethanol, and 1% sodium dodecylsulfate [SDS]), soni-
cated, and centrifuged for 20 min at 13,000 rpm at 4C.
An equal volume of 23 SDS gel-loading buffer was added
to 10 ml of supernatant, and the samples were boiled for
3 min. The proteins were separated by 15% SDS-polyacry-
lamide gel, transferred to nitrocellulose transfer mem-
brane, and probed with the indicated antibodies.
RESULTS
The monoclonal antibody T52 was produced by immu-
nization of mice with a peptide corresponding to the his-
tone H4 N-terminal tail carrying the four acetylated lysines
(K5, K8, K12, and K16). Western blotting (Fig. 1A) and
enzyme-linked immunosorbent assay (Fig. 1C) experi-
ments showed that it recognizes acetyl-lysine with vari-
able efﬁciency, with a preferential binding for histone H3
and H4 substrates, as opposed to a second monoclonal
antibody (T25), which recognizes speciﬁcally histone H4
carrying K8/K12 acetylated (Fig. 1B and 1C).
To test the possibility of performing histone acetylation
level analysis by ﬂow cytometry, exponentially growing
U937 cells were subjected to treatment with TSA. The
HDACi TSA binds to HDACs and inhibits their enzymatic
activity (14). The block of acetyl-group removal from
HDAC substrates leads to an overall increase in the num-
ber of acetylated proteins in the cell (of these proteins,
the vast majority is composed of histones).
T52, T25, and a commercial anti tetra-acetylated histone
H4 polyclonal antibody (Upstate) were employed, and
after optimization of the working dilutions, the obtained
results were compared (Fig. 2). All tested antibodies
showed a fourfold increase in the mean ﬂuorescence of
TSA-treated cells in comparison with control, untreated,
exponentially growing cells. Basal levels of acetylation
were measurable (compare curves BL and CTR in Fig. 2)
in these cells, as expected from the presence of acetylated
histones in cells under growing conditions and conﬁrmed
by western blotting experiments carried out in parallel
(data not shown). TSA dosage was chosen to maximize
acetylation effects at early time points but minimize cell
toxicity because increased concentration showed relevant
cell death starting from 24 h of incubation (data not
shown). Due to the comparable performances of the
tested reagents, all studies in the present work were per-
formed using the T52 antibody. Even if the antibody can
react with all acetylated histone isoforms and ‹-acetylated
lysine residues, in whole cell assays, the amounts of acety-
lated, non-histone proteins is negligible, and for practical
purposes the antibody can be considered as an anti-acety-
lated histone antibody as demonstrated by the obtained
results.
Biparametric T52/DNA analysis was then performed to
correlate histone acetylation levels with cell cycle (Fig. 3).
For parallel analysis of transcription, U937 cells were
exposed to the halogenated riboside BrU, which permeates
the cells and is assembled into mRNA, providing a mea-
sure of the global transcriptional activity (15–18). Com-
mercial antibodies available for detection of BrdU exhibits
cross-reactivity toward BrU and they can efﬁciently recog-
nize BrU-containing RNA. Denaturation of nucleic acids
(usually performed for detection of replicated DNA) was
omitted because the compound is part of single-stranded
RNA. Transcription levels showed a striking correlation
with cell cycle progression (Fig. 3A and 3D). Transcrip-
tional activity increased from G1 to S phase, and during
replication transcriptional levels paralleled the increase in
DNA content as demonstrated by the high correlation
coefﬁcient of the linear ﬁt between DNA and RNA mean
ﬂuorescence. As expected, G2/M cells showed diminished
BrU incorporation levels due to the reduced transcription
rate during the last phases of the cell cycle (Fig. 3D).
Histone acetylation levels presented similar distribu-
tions during the cell cycle, demonstrating the strict corre-
lation between chromatin modiﬁcations and RNA tran-
scription/DNA replication (Fig. 3B and 3E). Fluorescence
from T52 staining increased during S phase in proportion
to the PI signal (Fig. 3E), thus paralleling the growing
amount of histones during cell cycle progression. Similarly
to the observed transcriptional behavior, when cells pro-
ceeded through late S and G2M phases, the signal inten-
sity showed a decrement, indicating the enhanced activity
of HDACs in these phases of the cell cycle.
Figures 3C and 3F show how TSA treatment caused a
complete redistribution of acetylation signal throughout
the cell cycle. After 4 h of treatment of asynchronous
cells, when changes in cell cycle progression were not evi-
dent (data not shown), cells presented an evident increase
in the mean acetylation level (Fig. 3E–G). Moreover, acety-
lation level modiﬁcations showed a striking cell cycle
dependence with enhanced effects in G1 and G2M: TSA
fold increase (TSA treated vs. untreated cell mean ﬂuores-
cence) was almost constant through the S phase as
expected for a signal dependent mainly on the total
amount of histone present in the cells. The marked
increase in G1 and in G2M (even if less pronounced) cells
unmasked the already hypothesized enhanced HDAC
activity in these phases. As a further remark, histone acety-
lation ﬂuorescence from TSA-treated cells showed a high
linear correlation with all the DNA ﬂuorescence classes as
a result of a now complete dependence from the total
amount of histone (assumed to be proportional to the
DNA content) including the G1 and G2M sub-phases,
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which were displaced in their acetylation level intensity
with respect to the linear ﬁt in an exponentially growing
population.
The NB4 acute promyelocytic leukemia cell line can dif-
ferentiate to granulocytes after RA treatment, due in part
to RA-induced release of HDAC from the fusion protein
PML-RAR (19). NB4 cells were treated with RA, TSA, and
RA 1 TSA, and the effects on differentiation, histone acet-
ylation, transcription, and cell cycle were analyzed by
biparametric ﬂow cytometry.
Surface differentiation-marker analysis showed that RA
alone or in combination with TSA induced marked differ-
entiation after 48 h, whereas TSA administration showed
no effect (data not shown). Cell cycle progression was
transiently altered by treatment with TSA alone or in com-
bination with RA: cells showed a slight accumulation in
the G1 phase of the cell cycle at 24 h (Fig. 4B), which dis-
appeared at late time points. Transcription levels were not
dramatically affected during treatment with TSA, RA, or
RA 1 TSA at any examined time points as shown in Figure
4A (rows 2–4), with mean BrU ﬂuorescence level essen-
tially unchanged throughout the duration of drug treat-
ments (Fig. 4C).
TSA treatment led to HDAC inhibition/increased acetyla-
tion levels with a very fast kinetics. Histone acetylation
increased in all cell cycle phases after short incubation
with TSA (2 h; Fig. 5A, column 2), reaching a maximal
effect after 4 h of treatment (Fig. 5A, column 3). No effects
on global acetylation were observed at the same time
point or later in RA-treated NB4 cells (Fig. 5A). Simulta-
neous administration of RA and TSA marginally increased
histone acetylation levels if compared with TSA treatment.
Although TSA was maintained in the medium, acetylation
levels returned to basal conditions in 24 h, indicating that
the perturbation of the cell cycle and the acetylation mod-
iﬁcations (Fig. 4B) were temporally uncoupled. Drug
effects on acetylation levels completely disappeared after
48 h of treatment (Fig. 5, column 4).
FIG. 2. Monoparametric analysis of histone acetylation levels. A: Stained with mouse T52 antibody (5 mg/ml). B: Stained with mouse T25 antibody (1 mg/
ml). C: Stained with rabbit anti–acetyl-histone H4 (dilution 1:50l Upstate). D: Table of mean ﬂuorescence values (arbitrary units). BL, blank sample of U937
cells stained only with FITC-conjugated secondary antibody; CTR, U937 exponentially growing cells (control); TSA, U937 cells treated with 50 ng/ml of
TSA for 4 h.
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Detailed analysis of the correlation between histone
acetylation and cell cycle progression revealed the same
pattern previously observed in U937 cells: TSA-treated
cells loosed the typical downregulation of the acetylation
signal in the G1–early S and late S–G2M cell cycle phases.
Cells treated with TSA and with TSA 1 RA showed an
almost perfect linear correlation with DNA (histone) con-
tent. The maximal increase in histone acetylation ﬂuores-
cence is reached after 4 h of treatment in G1–S early com-
partment. Simultaneous administration of RA and TSA pro-
duced a slightly increased de-acetylation in the ﬁrst hours
of treatment (Fig. 5C, TSA/CTRL and TSA 1 RA/CTRL
curves). Ratio between histone acetylation mean ﬂuores-
cence in treated and control cells conﬁrmed the transient
effect of TSA and its disappearance at late time points.
HDACi currently represent one of the most promising
new treatments for anticancer therapy. Consequently,
new assays to test their activity in vivo are strongly
desired. After a ﬁrst preclinical validation phase con-
ducted on leukemic mice treated with HDACi (data not
shown), we decided to test the developed protocol for
clinical use. We analyzed blood samples from patients
affected by different tumors (solid tumors and leukemias)
and treated with VPA, a drug used for years in the cure of
epilepsy whose HDAC inhibition activity has been
recently demonstrated (20). In the case of leukemias, ana-
lysis of blast cells from peripheral blood or bone marrow
ago-aspirates will provide direct indication of the degree
of HDAC inhibition induced by the HDACi. Although the
analysis of normal cells from peripheral blood will not
necessarily correlate with the acetylation status of cancer
cells in the case of solid tumors, it may complement phar-
macokinetic data by providing functional clues on the
action of the drug and therefore acting as a possible surro-
gate marker. Figure 6 shows representative samples from
patients treated with a standard dosage of VPA (30 mg/kg/
day) and affected by breast cancer (Fig. 6A and 6B), colon
cancer (Fig. 6C and 6D), melanomas (Fig. 6E and 6F), and
leukemia (myeloproliferative disease in Fig. 6G and acute
myeloid leukemia in Fig. 6H). Histone acetylation levels
can be successfully measured with variable responses to
VPA observed from case to case.
DISCUSSION
In this study, we report for the ﬁrst time the develop-
ment of a ﬂow cytometric protocol for detection of his-
tone acetylation levels employing a mouse monoclonal
antibody against acetylated lysine (T52). Selective signal
increase after inhibition of HDACs demonstrated how the
antibodies can detect variations in the mean number of
acetyl groups (on all acetylated proteins for T52 and
exclusively on histone H4 for T25, not shown) in a cell
population.
Correlative analysis of DNA–histone acetylation levels
allowed for characterization of the acetylation process
during cell cycle. The entry in the replication phase was
associated with an increasing mean value in the anti-acety-
lated histone signal from T52 monoclonal antibody, paral-
leling the growth in histone content associated with DNA
duplication.
FIG. 3. Analysis of transcription and acetylation levels in correlation to cell cycle. A: Detection of transcription levels and cell cycle in exponentially grow-
ing U937 cells. Cells were incubated with 4 mM (2)-5-BrU for 30 min before ﬁxation. Biparametric analysis of histone acetylation levels and cell cycle in
(B) U937 exponentially growing cells and (C) U937 cells treated with 50 ng/ml of TSA for 4 h. D–F: Correlation between transcription (anti-BrU; D), his-
tone acetylation (T52; E, F) mean ﬂuorescence and DNA content in exponentially growing and TSA-treated cells. Values were calculated according to the
procedure explained in Materials and Methods. G: Ratios between histone acetylation levels in TSA-treated versus untreated cells were then calculated for
each DNA compartment showing an increased action of the drug in the G1–S early and late S–G2M phases.
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Previously published ﬂuorescence microscopy studies
showed a speciﬁc regulation of acetylation signals during
DNA replication. Maintenance of a heterochromatic state
requires recruitment of acetyltransferase CAF-1 on replica-
tion foci, causing speciﬁc H4 acetylation on lysines 5 and
12 (21). At the end of S phase, an increased HDAC activity
was instead observed in concomitance of recruitment of
HDAC2 on newly synthesized DNA (22). A precise timing
in the synthesis of expressed and silenced genes has been
consequently demonstrated, with the ﬁrst and middle S
phases devoted to replication of actively transcribed,
hyper-acetylated chromatin (euchromatin), whereas DNA
synthesis ends with silenced and hypo-acetylated chroma-
tin (heterochromatin) reconstitution (23). Our ﬂow cyto-
metric data well ﬁt into this scheme, as demonstrated by a
ﬁrst increase in histone acetylation signal detected in the
G1 to S phase transition and by the appearance of a subpo-
pulation characterized by lower acetylation signal close to
the tetraploid DNA content (late S to G2M cell cycle
phase) which can not simply related to the variation of
the total amount of histone present in the cells. Strikingly
a perfect correlation between acetylation-related ﬂuores-
cence and DNA content (considered as an indirect mea-
sure of histone content) is achieved after inhibition of
HDAC activity, demonstrating that only in this case the
T52 signal could reﬂect the total amount histone protein
FIG. 4. Biparametric analysis of
transcription levels and cell cycle.
During the last 30 min of treatment,
cells were incubated with 4 mM
(2)-5-BrU. A: Exponentially grow-
ing NB4 cells (row 1), NB4 cells
treated with 1 mM RA (row 2), NB4
cells treated with 50 ng/ml TSA
(row 3), and NB4 cells treated with
50 ng/ml TSA and 1 mM RA (row 4)
for 2, 4, 24, and 48 h. B: Cell cycle
phase distributions. C: Correlation
between transcription (anti-BrU)
mean ﬂuorescence and DNA con-
tent in exponentially growing and
treated cells. Values were calcula-
ted according to the procedure ex-
plained in Materials and Methods.
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present in the cells throughout the entire cell cycle. A par-
allel analysis on transcriptional activity measured by
BrdUrd incorporation levels provided a further correlation
of histone acetylation levels with transcription and repli-
cation, as demonstrated by the large amount of newly
transcribed RNA during DNA synthesis.
The developed ﬂow cytometric protocol allowed for
characterization of global transcription and chromatin
organization during hematopoietic differentiation. Analy-
sis of data obtained from the NB4 in vitro model showed
how creation of a chromatin environment favorable to
transcription by histone hyper-acetylation is not paralleled
by an increase in the effective transcription rate. HDACi
treatment does not consequently imply general unspeciﬁc
gene activation. Hyper-acetylation effects are located in a
very narrow temporal window in the ﬁrst hours of treat-
ment; repeated treatments could be consequently
requested to maintain HDAC inhibition over time.
The possibility to directly measure the activity of HDAC
inhibitors in vivo through analysis of peripheral blood cell
acetylation levels can provide a new parameter to comple-
ment classic analysis of drug treatment such as measure-
ment of compound levels in serum. Direct comparison of
side effects, drug concentration, and indirect drug activity
based on acetylation level detection in blood cells could
provide a more complete picture to be used in the design
of treatment plans and to frequently monitor compound
activity during clinical trials. Studies are in progress to test
FIG. 5. Biparametric analysis of histone
acetylation levels and cell cycle. A: Exponen-
tially growing NB4 cells (row 1), NB4 cells
treated with 1 mM RA (row 2), NB4 cells trea-
ted with 50 ng/ml TSA (row 3), and NB4 cells
treated with 50 ng/ml TSA and 1 mM RA (row
4) for 2, 4, 24, and 48 h. B: Correlation
between histone acetylation (T52) mean
ﬂuorescence and DNA content in exponen-
tially growing and treated cells at selected
time points during treatment. Values were
calculated according to the procedure
explained in Materials and Methods. C: Mea-
surement of acetylation variation in response
to TSA, RA, and TSA 1 RA treatments calcu-
lated as the ratio between histone acetylation
mean ﬂuorescence in treated and untreated
cells in function of the mean DNA content.
Each panel reports the measurement at the
indicated time point.
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the ability to directly measure HDAC inhibition in tumor
samples. Moreover, ﬂow cytometric analysis of histone
acetylation levels can open new promising perspectives
in the ﬁeld of tumor characterization and prognostic mar-
ker identiﬁcation. The protocol we developed can be efﬁ-
ciently employed for multivariate analysis to correlate his-
tone acetylation and DNA ploidy and/or expression of
known oncogenic factors.
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